Can we count your visit with Google Analytics? No ads, no profiles. Details
SLS
USHealth Care · Biotechnology
Each weekday: the watchlist of pullbacks inside uptrends, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
Free when you join: the $HOOD Teardown Dossier (Robinhood Markets), the full desk file we sell in the shop. One per new reader.
No spam. One email per day max, unsubscribe in one click. Pro ($49/mo) includes every dossier and report in the shop.
Structural: cancer immunotherapy is one of oncology's fastest-growing modalities; WT1 is overexpressed in a broad range of cancers (~20 tumor types), giving GPS a multi-indication runway beyond the lead AML and mesothelioma programs. Orphan Drug Designation in both lead indications reduces the required trial size and provides 7-year market exclusivity upon approval, materially lowering the capital cost to commercialization relative to a standard oncology program.
GPS Phase 3 REGAL trial in AML maintenance (post-remission setting) targets a disease with no approved maintenance immunotherapy and a 3-year relapse rate above 60%; a positive readout would address a validated clinical gap. The WT1 antigen is immunogenic and broadly expressed, supporting a potential label expansion strategy post-AML approval.
Mesothelioma is a second small-market, high-value indication where GPS has shown signal. Orphan status, Fast Track designation, and a focused management team reduce execution friction. Biotech acquirers routinely pay 4-10x premium on late-stage oncology assets.
SELLAS is entirely dependent on GPS -- a single-asset, single-mechanism company with no approved product and no revenue. Clinical-stage oncology has a high failure rate; a negative REGAL readout would likely be an existential event. Cash burn requires repeated equity raises, creating chronic dilution pressure at a sub-$200M market cap.
WT1 peptide vaccines have struggled historically to achieve durable clinical responses as monotherapies; combination strategy with checkpoint inhibitors has not been clinically validated at scale. Partnership or licensing deal dependency adds execution risk.
It reads our $SLS data (thesis, key levels, peers, a year of prices) and any chart screenshot you paste, then explains the setup in plain English. Free with an email login, 5 questions a day. Education only: it never tells you to buy or sell, and it can be wrong, so check the numbers.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.